Sequent Scientific Reports Strong Financial Growth and Improved Operational Efficiency in August 2025

Sequent Scientific, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 8, 2025, indicate a notable shift in the company's evaluation, with its score rising to 28 from 26 over the past three months. The financial data reveals several positive developments for Sequent Scientific. The Profit Before Tax less Other Income (PBT) reached Rs 22.90 crore, reflecting a significant year-on-year growth of 145.71%. Similarly, the Profit After Tax (PAT) stood at Rs 15.17 crore, marking a year-on-year increase of 133.0%. In terms of operational efficiency, the company achieved its highest Operating Profit to Interest ratio at 3.69 times in the last five quarters, indicating an improvement in its ability to manage interest payments. Net Sales also peaked at Rs 441.42 crore, while Operating Profit (PBDIT) reached Rs 52.19 crore, both representing the highest figures in the last five quarters. The Operating Profit Margin improved to 11.82%, showcasing enhanced efficiency. Additionally, Earnings per Share (EPS) hit Rs 0.57, indicating increased profitability for shareholders. Overall, these results suggest a positive trajectory for Sequent Scientific, leading to an adjustment in its evaluation. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.